Theranostic Prospects of Gastrin-Releasing Peptide Receptor-Radioantagonists in Oncology.

Theranostic Prospects of Gastrin-Releasing Peptide Receptor-Radioantagonists in Oncology. PET Clin. 2017 Jul;12(3):297-309 Authors: Maina T, Nock BA, Kulkarni H, Singh A, Baum RP Abstract Gastrin-releasing peptide receptors (GRPRs) represent attractive targets for cancer diagnosis and therapy owing to their overexpression in widespread human tumors. Bombesin (BBN) analogues coupled to suitable chelators for stable radiometal binding have been proposed for diagnostic imaging and radionuclide therapy (theranostics) of GRPR-positive tumors. Recently, interest has shifted from BBN-like receptor agonists to GRPR-radioantagonists, because radioantagonists do not induce adverse effects after injection to patients and display superior pharmacokinetic in vivo profiles. Thus, they seem more advantageous for clinical use compared to agonists. Newer developments highlighting the theranostic potential of GRPR-radioantagonists in cancer patient management are presented herein. PMID: 28576168 [PubMed - in process]
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: PET Clin Source Type: research